Mesenchymal stem cells genetically modified by lentivirus‑mediated interleukin‑12 inhibit malignant ascites in mice

Han,Jiming; Zhao,Jumei; Xu,Jianrong; Wen,Yanjun

doi:10.3892/etm.2014.1918

October 2014 Volume 8 Issue 4

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

October 2014 Volume 8 Issue 4

Full Size Image

Article

Mesenchymal stem cells genetically modified by lentivirus‑mediated interleukin‑12 inhibit malignant ascites in mice

Authors:
- Jiming Han
- Jumei Zhao
- Jianrong Xu
- Yanjun Wen
View Affiliations / Copyright

Affiliations: Medical College of Yan'an University, Yan'an, Shaanxi 716000, P.R. China, Southwest University of Science and Technology, Mianyang, Sichuan 621010, P.R. China, State Key Laboratory of Biotherapy, West China Hospital, Sichuan University, Chengdu, Sichuan 610041, P.R. China
Pages: 1330-1334
|
Published online on: August 19, 2014

https://doi.org/10.3892/etm.2014.1918
Expand metrics +

Abstract

The objective of the present study was to investigate the effects of mesenchymal stem cells (MSCs) genetically modified by lentivirus‑mediated mouse interleukin‑12 (Lenti‑mIL‑12) in treating malignant ascites in mice. The in vitro chemotactic effect of Lenti‑mIL‑12‑MSC culture supernatant on dendritic cells was investigated using a chemotaxis chamber. Liver cancer H22 and MethA ascites models were constructed. Mice were divided evenly into four groups: Normal saline, MSC, Null and Lenti‑mIL‑12‑MSC. The survival rate, ascites volume and red blood cell number were measured for these groups. The toxicity and side effects of Lenti‑mIL‑12‑MSCs were investigated using visual and microscopy inspections. The results indicated that mIL‑12 had a strong chemotactic effect on dendritic cells. mIL‑12 was highly expressed in ascites of Lenti‑mIL‑12‑MSC‑treated mice. Lenti‑mIL‑12‑MSCs reduced the volume of ascites and the number of red blood cells in ascites and thus increased the survival rate and prolonged the survival duration of the mice. Furthermore, Lenti‑mIL‑12‑MSCs showed no toxicity and side effects on the mice with malignant ascites. In conclusion, the results demonstrated that Lenti‑mIL‑12‑MSCs inhibited the growth of ascites and promoted the survival of tumor‑bearing mice, suggesting that Lenti‑mIL‑12‑MSCs exerts a therapeutic effect on malignant ascites by stimulating the immune responses of the mice.

View Figures

View References

1	Scheithauer W, Kornek GV, Raderer M, et al: Randomized multicenter phase II trial of two different schedules of capecitabine plus oxaliplatin as first-line treatment in advanced colorectal cancer. J Clin Oncol. 21:1307–1312. 2003. View Article : Google Scholar : PubMed/NCBI
2	Santini D, Massacesi C, D’Angelillo RM, et al: Raltitrexed plus weekly oxaliplatin as first-line chemotherapy in metastatic colorectal cancer: a multicenter non-randomized phase ii study. Med Oncol. 21:59–66. 2004. View Article : Google Scholar : PubMed/NCBI
3	Sartori S, Nielsen I, Tassinari D, Trevisani L, Abbasciano V and Malacarne P: Evaluation of a standardized protocol of intracavitary recombinant interferon alpha-2b in the palliative treatment of malignant peritoneal effusions. A prospective pilot study. Oncology. 61:192–196. 2001. View Article : Google Scholar
4	Walther W and Schlag PM: Current status of gene therapy for cancer. Curr Opin Oncol. 25:659–664. 2013. View Article : Google Scholar : PubMed/NCBI
5	Yoshiji H, Kuriyama S, Hicklin DJ, et al: The vascular endothelial growth factor receptor KDR/Flk-1 is a major regulator of malignant ascites formation in the mouse hepatocellular carcinoma model. Hepatology. 33:841–847. 2001. View Article : Google Scholar
6	Cheema TA, Fecci PE, Ning J and Rabkin SD: Immunovirotherapy for the treatment of glioblastoma. Oncoimmunology. 3:e272182014. View Article : Google Scholar : PubMed/NCBI
7	Marchi LH, Paschoalin T, Travassos LR and Rodrigues EG: Gene therapy with interleukin-10 receptor and interleukin-12 induces aprotective interferon-γ-dependent response against B16F10-Nex2 melanoma. Cancer Gene Ther. 18:110–122. 2011.PubMed/NCBI
8	Quetglas JI, Dubrot J, Bezunartea J, et al: Immunotherapeutic synergy between anti-CD137 mAb and intratumoral administration of a cytopathic Semliki Forest virus encoding IL-12. Mol Ther. 20:1664–1675. 2012. View Article : Google Scholar : PubMed/NCBI
9	Dickerson EB, Akhtar N, Steinberg H, et al: Enhancement of the antiangiogenic activity of interleukin-12 by peptide targeted delivery of the cytokine to alphavbeta3 integrin. Mol Cancer Res. 2:663–673. 2004.PubMed/NCBI
10	Wigginton JM, Gruys E, Geiselhart L, et al: IFN-gamma and Fas/FasL are required for the antitumor and antiangiogenic effects of IL-12/pulse IL-2 therapy. J Clin Invest. 108:51–62. 2001. View Article : Google Scholar : PubMed/NCBI
11	Zhang L, Kerkar SP, Yu Z, et al: Improving adoptive T cell therapy by targeting and controlling IL-12 expression to the tumor environment. Mol Ther. 19:751–759. 2011. View Article : Google Scholar : PubMed/NCBI
12	Kerkar SP, Muranski P, Kaiser A, et al: Tumor-specific CD8⁺ T cells expressing interleukin-12 eradicate established cancers in lymphodepleted hosts. Cancer Res. 70:6725–6734. 2010.PubMed/NCBI
13	Parker JN, Meleth S, Hughes KB, Gillespie GY, Whitley RJ and Markert JM: Enhanced inhibition of syngeneic murine tumors by combinatorial therapy with genetically engineered HSV-1 expressing CCL2 and IL-12. Cancer Gene Ther. 12:359–368. 2005. View Article : Google Scholar : PubMed/NCBI
14	Dai LJ, Moniri MR, Zeng ZR, et al: Potential implications of mesenchymal stem cells in cancer therapy. Cancer Lett. 305:8–20. 2011. View Article : Google Scholar : PubMed/NCBI
15	Bexell D, Svensson A and Bengzon J: Stem cell-based therapy for malignant glioma. Cancer Treat Rev. 39:358–365. 2013. View Article : Google Scholar : PubMed/NCBI
16	Hu YL, Fu YH, Tabata Y and Gao JQ: Mesenchymal stem cells: a promising targeted-delivery vehicle in cancer gene therapy. J Control Release. 147:154–162. 2010. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Mesenchymal stem cells genetically modified by lentivirus‑mediated interleukin‑12 inhibit malignant ascites in mice

This article is mentioned in:

Abstract

Figure 1

Figure 2

Figure 3

Related Articles